. . . "The primary route of excretion in man is via the urine as both inamrinone and several metabolites (N-glycolyl, N-acetate, O-glucuronide and N-glucuronide)."@en . . . "5 to 8 hours"@en . . "Amrinone"@en . . . . " "@en . . . . . "approved"@en . . "Amcoral"@en . . "Humans and other mammals"@en . "Used in the treatment of congestive heart failure."@en . "Amrinone is a phosphodiesterase inhibitor (PDE3), resulting in increased cAMP and cGMP which leads to an increase in the calcium influx like that caused by beta-agonists resulting in increased inotropic effect."@en . . . . . . . . . . "Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure."@en . . . "Lesher,G.Y. and Opalka, C.J.; US. Patent 4,004,012; January 18,1977; assigned to Sterling Drug Inc. Lesher, G.Y. and Opalka, C.J.; U.S. Patent 4,107,315; August 15,1978; assigned to Sterling Drug Inc."@en . . "Amrinonum"@en . . . . . . . . . . . . . "* 1.2 L/kg [normal volunteers]"@en . . "10 to 49%"@en . . "Amrinona"@en . "Inamrinone"@en . "60719-84-8"@en . . . . .